United States Premenstrual Syndrome (PMS) Treatment Market Size & Forecast 2025–2033

According to Renub Research United States Premenstrual Syndrome Treatment Market is projected to expand steadily from US$ 517.31 Million in 2024 to nearly US$ 730.58 Million by 2033, growing at a CAGR of 3.91% between 2025 and 2033. Market growth is fueled by increasing awareness regarding women’s reproductive health, rising diagnosis rates, improved access to healthcare, and the availability of advanced pharmacological and non-pharmacological treatment options. The expanding role of telemedicine, growth in wellness infrastructure, and increasing preference for natural and non-hormonal therapies are also supporting sustained market development.

United States Premenstrual Syndrome Treatment Market Outlook

Premenstrual Syndrome (PMS) encompasses a wide spectrum of physical, emotional, and behavioral symptoms, including mood swings, fatigue, bloating, irritability, and headaches, typically occurring during the luteal phase of the menstrual cycle. Treatment approaches in the United States span lifestyle interventions, over-the-counter pain medications, hormonal therapies, antidepressants, and supportive wellness therapies.

Growing recognition of PMS as a legitimate health issue has reduced stigma and encouraged more women to seek clinical support. Extensive awareness campaigns, social media discussions, and women’s wellness initiatives are driving proactive diagnosis and treatment adoption. Telehealth platforms further expand access, allowing virtual consultations, digital symptom tracking, and prescription fulfillment, making care more convenient and personalized.

Download Free Sample Report:https://www.renub.com/request-sample-page.php?gturl=united-states-pms-treatment-market-p.php

Key Market Growth Drivers

Rising Awareness and Diagnosis Rates

Increasing educational outreach by healthcare institutions, advocacy bodies, and women’s health brands has improved understanding of PMS and its impact on quality of life. With more than 90% of women reporting PMS symptoms at some point, the U.S. healthcare system now places stronger emphasis on timely diagnosis and comprehensive symptom management. Workplace wellness programs, social media advocacy, and telehealth consultations are contributing to greater treatment uptake.

Expansion of Women’s Healthcare and Wellness Infrastructure

Significant investments in gynecology clinics, women’s health centers, and hormonal wellness programs have improved access to specialized care. Insurance expansion, growing hospital networks, and digital consultations are enabling cost-effective management. Holistic treatment planning—combining prescription medications, therapy, supplements, and lifestyle coaching—supports better patient outcomes.

Growing Adoption of Non-Hormonal and Natural Therapies

Concerns related to hormonal side effects and long-term medication reliance are encouraging U.S. consumers to seek herbal supplements, vitamins, OTC pain relievers, yoga-based therapy, and stress management solutions. Nutraceuticals and clean-label wellness products are rapidly gaining acceptance, while new pain management drugs and safer therapies are enhancing treatment innovation.

Key Market Challenges

Lack of Standardized Diagnostic Criteria

Variability in symptoms and overlap with conditions such as anxiety or thyroid disorders complicate diagnosis. Self-medication without physician guidance and uneven awareness—especially across underserved communities—limit clinical treatment penetration.

Drug Side Effects and Limited Efficacy for Some Patients

SSRIs, hormonal drugs, and other medications may cause adverse reactions such as nausea, mood shifts, weight gain, or sleep disturbance, resulting in discontinuation or low adherence. Continued pharmaceutical innovation is required to deliver safer, targeted therapeutic options.

Segment Insights

Analgesics PMS Treatment Market

NSAIDs such as ibuprofen and naproxen dominate for rapid relief of cramps, headaches, and musculoskeletal discomfort. Rising preference for self-care, accessible OTC solutions, and improved long-acting formulations strengthens demand.

Antidepressants PMS Treatment Market

SSRIs, including fluoxetine and sertraline, form a critical therapy class for women with severe mood-linked PMS and PMDD. Telepsychiatry, mental health integration, and growing acceptance of psychological treatment approaches are expanding segment growth.

Prescription PMS Treatment Market

Increasing medical consultations and broader understanding of hormonal imbalances are supporting rising demand for hormonal contraceptives, antidepressants, and diuretics. Insurance coverage improvements, combination therapy development, and telehealth-driven prescription convenience sustain growth.

Hospital Pharmacies Market

Hospital pharmacies play a major role in dispensing advanced therapies and managing clinically severe PMS or PMDD cases. Integration of multidisciplinary care teams enhances treatment accuracy and patient outcomes.

Online Stores Market

E-pharmacy platforms are witnessing robust growth driven by privacy needs, convenience, subscription services, teleconsultations, and wide product availability. However, regulation and counterfeit risks require careful oversight.

Regional Highlights (Selected States)

California

High awareness levels, strong wellness culture, leading healthcare facilities, and advanced telemedicine adoption make California one of the most progressive markets for PMS treatment.

New Jersey

Close proximity to major pharmaceutical hubs and strong healthcare infrastructure promotes availability of advanced therapeutic solutions and awareness initiatives.

Washington

Emphasis on preventative healthcare, personalized therapy programs, and high digital health adoption contribute to Washington’s growing PMS treatment market strength.

Market Segmentation

By Drug Type:
Analgesics | Antidepressants | Oral Contraceptives & Ovarian Suppression Agents | Others

By Type:
Prescription | Over-the-Counter

By Distribution Channel:
Hospital Pharmacies | Drug Stores & Retail Pharmacies | Online Stores

Top Geographic Markets:
California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio, Georgia, New Jersey, Washington, and others

Competitive Landscape

All companies are profiled with Overview, Key Persons, Recent Developments, SWOT Analysis, and Revenue Performance.
Key market participants include:

AbbVie Inc. | BASF SE | Bayer AG | Dr. Reddy’s Laboratories Ltd. | Eli Lilly and Company | GlaxoSmithKline Plc. | H. Lundbeck A/S | Pfizer Inc. | SHIONOGI & Co. Ltd.